Pinpoint Therapeutics

About:

Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.

Website: https://www.pinpointtherapeutics.com/

Twitter/X: PennPCI

Top Investors: Kairos Ventures

Description:

Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy, a key cell survival and treatment resistance pathway in cancer. Pinpoint inhibitors target a recently discovered enzyme in the autophagy pathway called PPT1, which is highly expressed across most cancers. These inhibitors could be applied to a broad range of cancers alone or in combination to overcome therapy resistance.

Total Funding Amount:

$1M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Philadelphia, Pennsylvania, United States

Founded Date:

2018-01-01

Contact Email:

pciinfo(AT)pci.upenn.edu

Founders:

Jeffrey Winkler, Ravi Amaravadi

Number of Employees:

51-100

Last Funding Date:

2019-12-30

IPO Status:

Private

Industries:

© 2025 bioDAO.ai